AbbVie stock reached a new 52-week high on Monday, rising about 40% over the past 12 months. The healthcare giant recently announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology portfolio. Despite the rally, AbbVie trades at less than 18 times estimated future earnings, below the S&P 500 average of 21. The company has demonstrated solid resiliency with strong financials and an above-average dividend yielding 2.7%. Analysts suggest the stock remains an attractive long-term buy despite the elevated share price.
AbbVie IncAbbVie announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology portfolio, driving stock to a 52-week high.
Apogee Therapeutics, Inc. Common StockApogee Therapeutics is being acquired by AbbVie for $10.9 billion, a premium that benefits its shareholders.